Supernus Pharmaceuticals (SUPN) Accumulated Expenses (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Accumulated Expenses data on file, last reported at $189.7 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $189.7 million, up 146.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $189.7 million (up 146.74% YoY), and the FY2025 annual result was $107.8 million, down 36.1% from the prior year.
• Accumulated Expenses climbed to $189.7 million in Q1 2026 per SUPN's latest filing, from $107.8 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $189.7 million in Q1 2026 and troughed at $76.9 million in Q1 2025.
• A 5-year average of $131.6 million and a median of $140.2 million in 2022 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2026: Accumulated Expenses tumbled 47.54% in 2023, then surged 146.74% in 2026.
• A 5-year view of Accumulated Expenses shows it stood at $151.7 million in 2022, then plunged by 47.54% to $79.6 million in 2023, then jumped by 112.02% to $168.7 million in 2024, then plunged by 36.1% to $107.8 million in 2025, then soared by 75.99% to $189.7 million in 2026.
• Business Quant data shows SUPN's Accumulated Expenses at $189.7 million in Q1 2026, $107.8 million in Q4 2025, and $184.5 million in Q3 2025.